Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose

Adva Cahen-Peretz; Lilah Tsaitlin-Mor; Hadas Allouche Kam; Racheli Frenkel; Maor Kabessa; Sarah M. Cohen; Michal Lipschuetz; Esther Oiknine-Djian; Sapir Lianski; Debra Goldman-Wohl; Asnat Walfisch; Michal Kovo; Michal Neeman; Dana G. Wolf; Simcha Yagel; Ofer Beharier

doi:10.1172/jci.insight.158646

Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose

Adva Cahen-Peretz
, Lilah Tsaitlin-Mor
, Hadas Allouche Kam
, Racheli Frenkel
, Maor Kabessa
, Sarah M. Cohen
, Michal Lipschuetz
, Esther Oiknine-Djian
, Sapir Lianski
, Debra Goldman-Wohl
, Asnat Walfisch
, Michal Kovo
, Michal Neeman
, Dana G. Wolf
, Simcha Yagel
, Ofer Beharier

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

BACKGROUND. To minimize COVID-19 pandemic burden and spread, 3-dose vaccination campaigns commenced worldwide. Since patients who are pregnant are at increased risk for severe disease, they were recently included in that policy, despite the lack of available evidence regarding the impact of a third boosting dose during pregnancy, underscoring the urgent need for relevant data. We aimed to characterize the effect of the third boosting dose of mRNA Pfizer BNT162b2 vaccine in pregnancy. METHODS. We performed a prospective cohort study of anti–SARS-CoV-2 antibody titers (n = 213) upon delivery in maternal and cord blood of naive fully vaccinated parturients who received a third dose (n = 86) as compared with 2-dose recipients (n = 127). RESULTS. We found a robust surge in maternal and cord blood levels of anti–SARS-CoV-2 titers at the time of delivery, when comparing pregnancies in which the mother received a third boosting dose with 2-dose recipients. The effect of the third boosting dose remained significant when controlling for the trimester of last exposure, suggesting additive immunity extends beyond that obtained after the second dose. Milder side effects were reported following the third dose, as compared with the second vaccine dose, among the fully vaccinated group. CONCLUSION. The third boosting dose of mRNA Pfizer BNT162b2 vaccine augmented maternal and neonatal immunity with mild side effects. These data provide evidence to bolster clinical and public health guidance, reassure patients, and increase vaccine uptake among patients who are pregnant.

Original language	English
Article number	e158646
Journal	JCI insight
Volume	8
Issue number	1
DOIs	https://doi.org/10.1172/jci.insight.158646
State	Published - 10 Jan 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023, Cahen-Peretz et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Funding

This work was supported by an Israel Science Foundation KillCorona grant 3777/19 and a research grant from the “Ofek” Program of the Hadassah Medical Center. We would like to thank the patients who made this research possible. We acknowledge the invaluable contributions to patient recruitment and sample preparation made by Sarah Ben Haim, Tamar Chemla, and Nadine Souri, from the Hadassah Medical Center, Jerusalem. FUNDING. Israel Science Foundation KillCorona grant 3777/19; Research grant from the “Ofek” Program of the Hadassah Medical Center.

Funders	Funder number
Israel Science Foundation KillCorona	3777/19
Hadassah Medical Organization

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1172/jci.insight.158646

Cite this

Cahen-Peretz, A., Tsaitlin-Mor, L., Kam, H. A., Frenkel, R., Kabessa, M., Cohen, S. M., Lipschuetz, M., Oiknine-Djian, E., Lianski, S., Goldman-Wohl, D., Walfisch, A., Kovo, M., Neeman, M., Wolf, D. G., Yagel, S., & Beharier, O. (2023). Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose. JCI insight, 8(1), Article e158646. https://doi.org/10.1172/jci.insight.158646

@article{ac6f3ac8814641b6a7ac839fb9336fea,

title = "Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose",

abstract = "BACKGROUND. To minimize COVID-19 pandemic burden and spread, 3-dose vaccination campaigns commenced worldwide. Since patients who are pregnant are at increased risk for severe disease, they were recently included in that policy, despite the lack of available evidence regarding the impact of a third boosting dose during pregnancy, underscoring the urgent need for relevant data. We aimed to characterize the effect of the third boosting dose of mRNA Pfizer BNT162b2 vaccine in pregnancy. METHODS. We performed a prospective cohort study of anti–SARS-CoV-2 antibody titers (n = 213) upon delivery in maternal and cord blood of naive fully vaccinated parturients who received a third dose (n = 86) as compared with 2-dose recipients (n = 127). RESULTS. We found a robust surge in maternal and cord blood levels of anti–SARS-CoV-2 titers at the time of delivery, when comparing pregnancies in which the mother received a third boosting dose with 2-dose recipients. The effect of the third boosting dose remained significant when controlling for the trimester of last exposure, suggesting additive immunity extends beyond that obtained after the second dose. Milder side effects were reported following the third dose, as compared with the second vaccine dose, among the fully vaccinated group. CONCLUSION. The third boosting dose of mRNA Pfizer BNT162b2 vaccine augmented maternal and neonatal immunity with mild side effects. These data provide evidence to bolster clinical and public health guidance, reassure patients, and increase vaccine uptake among patients who are pregnant.",

author = "Adva Cahen-Peretz and Lilah Tsaitlin-Mor and Kam, \{Hadas Allouche\} and Racheli Frenkel and Maor Kabessa and Cohen, \{Sarah M.\} and Michal Lipschuetz and Esther Oiknine-Djian and Sapir Lianski and Debra Goldman-Wohl and Asnat Walfisch and Michal Kovo and Michal Neeman and Wolf, \{Dana G.\} and Simcha Yagel and Ofer Beharier",

note = "Publisher Copyright: {\textcopyright} 2023, Cahen-Peretz et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.",

year = "2023",

month = jan,

day = "10",

doi = "10.1172/jci.insight.158646",

language = "אנגלית",

volume = "8",

journal = "JCI insight",

issn = "2379-3708",

publisher = "American Society for Clinical Investigation",

number = "1",

}

Cahen-Peretz, A, Tsaitlin-Mor, L, Kam, HA, Frenkel, R, Kabessa, M, Cohen, SM, Lipschuetz, M, Oiknine-Djian, E, Lianski, S, Goldman-Wohl, D, Walfisch, A, Kovo, M, Neeman, M, Wolf, DG, Yagel, S & Beharier, O 2023, 'Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose', JCI insight, vol. 8, no. 1, e158646. https://doi.org/10.1172/jci.insight.158646

TY - JOUR

T1 - Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose

AU - Cahen-Peretz, Adva

AU - Tsaitlin-Mor, Lilah

AU - Kam, Hadas Allouche

AU - Frenkel, Racheli

AU - Kabessa, Maor

AU - Cohen, Sarah M.

AU - Lipschuetz, Michal

AU - Oiknine-Djian, Esther

AU - Lianski, Sapir

AU - Goldman-Wohl, Debra

AU - Walfisch, Asnat

AU - Kovo, Michal

AU - Neeman, Michal

AU - Wolf, Dana G.

AU - Yagel, Simcha

AU - Beharier, Ofer

PY - 2023/1/10

Y1 - 2023/1/10

N2 - BACKGROUND. To minimize COVID-19 pandemic burden and spread, 3-dose vaccination campaigns commenced worldwide. Since patients who are pregnant are at increased risk for severe disease, they were recently included in that policy, despite the lack of available evidence regarding the impact of a third boosting dose during pregnancy, underscoring the urgent need for relevant data. We aimed to characterize the effect of the third boosting dose of mRNA Pfizer BNT162b2 vaccine in pregnancy. METHODS. We performed a prospective cohort study of anti–SARS-CoV-2 antibody titers (n = 213) upon delivery in maternal and cord blood of naive fully vaccinated parturients who received a third dose (n = 86) as compared with 2-dose recipients (n = 127). RESULTS. We found a robust surge in maternal and cord blood levels of anti–SARS-CoV-2 titers at the time of delivery, when comparing pregnancies in which the mother received a third boosting dose with 2-dose recipients. The effect of the third boosting dose remained significant when controlling for the trimester of last exposure, suggesting additive immunity extends beyond that obtained after the second dose. Milder side effects were reported following the third dose, as compared with the second vaccine dose, among the fully vaccinated group. CONCLUSION. The third boosting dose of mRNA Pfizer BNT162b2 vaccine augmented maternal and neonatal immunity with mild side effects. These data provide evidence to bolster clinical and public health guidance, reassure patients, and increase vaccine uptake among patients who are pregnant.

AB - BACKGROUND. To minimize COVID-19 pandemic burden and spread, 3-dose vaccination campaigns commenced worldwide. Since patients who are pregnant are at increased risk for severe disease, they were recently included in that policy, despite the lack of available evidence regarding the impact of a third boosting dose during pregnancy, underscoring the urgent need for relevant data. We aimed to characterize the effect of the third boosting dose of mRNA Pfizer BNT162b2 vaccine in pregnancy. METHODS. We performed a prospective cohort study of anti–SARS-CoV-2 antibody titers (n = 213) upon delivery in maternal and cord blood of naive fully vaccinated parturients who received a third dose (n = 86) as compared with 2-dose recipients (n = 127). RESULTS. We found a robust surge in maternal and cord blood levels of anti–SARS-CoV-2 titers at the time of delivery, when comparing pregnancies in which the mother received a third boosting dose with 2-dose recipients. The effect of the third boosting dose remained significant when controlling for the trimester of last exposure, suggesting additive immunity extends beyond that obtained after the second dose. Milder side effects were reported following the third dose, as compared with the second vaccine dose, among the fully vaccinated group. CONCLUSION. The third boosting dose of mRNA Pfizer BNT162b2 vaccine augmented maternal and neonatal immunity with mild side effects. These data provide evidence to bolster clinical and public health guidance, reassure patients, and increase vaccine uptake among patients who are pregnant.

UR - https://www.scopus.com/pages/publications/85145956600

U2 - 10.1172/jci.insight.158646

DO - 10.1172/jci.insight.158646

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36625348

AN - SCOPUS:85145956600

SN - 2379-3708

VL - 8

JO - JCI insight

JF - JCI insight

IS - 1

M1 - e158646

ER -

Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this